Shares of Tilray Brands, Inc. (NASDAQ:TLRY – Get Free Report) fell 1.8% during trading on Tuesday after TD Cowen lowered their price target on the stock from $7.00 to $5.00. TD Cowen currently has a buy rating on the stock. Tilray Brands traded as low as $4.27 and last traded at $4.38. Approximately 3,408,133 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 4,245,552 shares. The stock had previously closed at $4.46.
Several other research analysts have also recently weighed in on the company. Roth Capital upgraded Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Thursday, April 2nd. Wall Street Zen raised Tilray Brands from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings downgraded Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Finally, ATB Cormark Capital Markets reduced their price objective on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating on the stock in a research report on Thursday, April 2nd. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $11.00.
Insider Activity
Trending Headlines about Tilray Brands
Here are the key news stories impacting Tilray Brands this week:
- Positive Sentiment: TD Cowen kept a Buy rating on Tilray Brands while setting a new $5.00 target, which still implies upside from recent trading levels. Benzinga article
- Neutral Sentiment: Tilray said it will report fourth-quarter and full fiscal 2026 results on July 28, which may create anticipation but is not itself a financial update. GlobeNewswire article
- Neutral Sentiment: BrewDog Waterloo, a Tilray-owned asset, announced a major semifinal watch party event, highlighting ongoing marketing activity in its beverage business. GlobeNewswire article
- Negative Sentiment: Analysts’ average rating on Tilray remains “Hold,” indicating investors are still waiting for clearer evidence of sustained improvement. American Banking News article
Hedge Funds Weigh In On Tilray Brands
Institutional investors and hedge funds have recently bought and sold shares of the company. Hilton Head Capital Partners LLC purchased a new stake in shares of Tilray Brands in the 4th quarter valued at approximately $38,000. Essential Partners LLC increased its holdings in shares of Tilray Brands by 110,137.5% during the 1st quarter. Essential Partners LLC now owns 8,819 shares of the company’s stock worth $57,000 after buying an additional 8,811 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Tilray Brands during the 4th quarter valued at approximately $126,000. R Squared Ltd purchased a new stake in shares of Tilray Brands during the 1st quarter valued at approximately $94,000. Finally, Apollon Wealth Management LLC acquired a new position in Tilray Brands in the first quarter valued at approximately $96,000. 9.35% of the stock is currently owned by institutional investors and hedge funds.
Tilray Brands Stock Down 1.8%
The stock has a market capitalization of $510.49 million, a price-to-earnings ratio of -0.32 and a beta of 1.89. The business has a fifty day moving average of $5.03 and a 200 day moving average of $6.75. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.79 and a quick ratio of 1.66.
About Tilray Brands
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
Further Reading
- Five stocks we like better than Tilray Brands
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
